00:00EP67 is a small peptide, or a small protein, which is in our immune cells, which are complement anaphylotoxin receptors,
00:13like C5AR1, bind them and activate the signaling.
00:16And it activates the receptors at a lower level, which means it activates the immune response. And with vaccines, this
00:29is an adjuvant, which helps to increase the immune response.
00:35Sir, can you get a new vaccine for COVID-19, Dengu, TB, or other patients with new vaccines?
00:43Our hope is that because we are using the host-derived immune response, this can be a generic solution to
00:54increase the number of vaccines, and there is still a number of other conditions.
01:01Sir, how much time can you use this technique before using vaccines?
01:06Sir, how much time can you use this technique before using the vaccine?
01:09Sir, how much time can you use this technique before using the vaccine?
01:31Sir, how much time can you use this technique before using the vaccine?
01:39It will become a way to use the vaccine in order to fully use the vaccine.
01:44Sir, how much more anti-biotic bacteria is compared to the MRSA,
01:48and how much more EP67 can it be?
01:51How much more can it be used to develop the new treatment of Santraman?
01:56I have seen in some studies,
02:00such as in the past,
02:03that the Staphylococcus aureus is a bacteria
02:06which also shows the antibiotic resistance.
02:10This particular peptide gives a good response
02:16that it doesn't grow its colonies
02:19and helps its clearance quickly.
02:23So, I hope that this can be used as an antibacterial molecule.
02:29So, we will do the best work in this world.
02:31However, there is still a lot of work in this world.
Comments